Resistance Mechanisms in Eukaryotic Pathogens

Eukaryotic pathogens—fungi and parasites—evolve resistance to the drugs used against them by the same broad routes as other microbes: altering the drug target, removing or detoxifying the drug, or amplifying the targeted pathway. Because the usable drug classes are few, resistance in fungi and parasites is a particularly serious constraint on therapy and is increasingly recognized as a global health and food-security concern.

Definition

Resistance in eukaryotic pathogens is the heritable reduction in a fungal or parasitic organism's susceptibility to a drug, arising from changes such as target-site mutation or overexpression, increased drug efflux, reduced uptake or activation, and bypass or amplification of the targeted pathway.

Scope

The topic surveys the general mechanisms by which fungi and parasites become resistant to antifungal and antiparasitic drugs, using antifungal azole and echinocandin resistance and antimalarial resistance as principal examples. It treats resistance as a biological and pharmacological phenomenon. It does not offer treatment, susceptibility-testing interpretation, or dosing guidance for individual cases.

Core questions

• What molecular routes produce resistance in fungi and parasites?
• How do target mutation and drug efflux contribute to antifungal resistance?
• Why is the emergence of antifungal and antimalarial resistance a global concern?

Key concepts

• Target-site mutation (e.g., ERG11/CYP51 in azole resistance, FKS in echinocandin resistance)
• Target overexpression and pathway amplification
• Drug efflux pumps
• Reduced uptake or impaired intracellular activation
• Stress responses and tolerance as precursors to resistance
• Environmental selection of resistance
• Resistance as a constraint given few drug classes

Mechanisms

In fungi, azole resistance commonly arises from mutations in the target gene ERG11/CYP51 that reduce drug binding, from overexpression of that target, and from upregulation of efflux pumps that lower intracellular drug concentration; echinocandin resistance typically arises from mutations in the FKS genes encoding the glucan-synthase target. Stress-response pathways can confer drug tolerance that provides a foothold for resistance to develop. In parasites, antimalarial resistance has emerged repeatedly through changes that alter drug accumulation or the parasite's response, with reduced artemisinin susceptibility manifest as slowed parasite clearance. Across eukaryotic pathogens, the recurring routes are altered or amplified target, reduced effective drug exposure (efflux, uptake, activation), and pathway bypass, with selection driven by drug pressure in clinical and, for some fungi, environmental settings.

Clinical relevance

Resistance narrows already limited therapeutic options for invasive fungal infections and for malaria, making its detection and the stewardship of existing drugs important for preserving efficacy. This entry explains the biology of resistance for educational reference and does not provide guidance on managing resistant infections in individual patients.

Epidemiology

Antifungal resistance has been reported across multiple pathogens and settings and is regarded as an emerging threat to human health and food security, while antimalarial resistance—most notably reduced artemisinin susceptibility first documented in Southeast Asia—has been a recurring obstacle to malaria control.

History

Resistance has shadowed antiparasitic and antifungal therapy throughout their history, from successive waves of antimalarial resistance that retired older drugs to the spread of azole-resistant fungi. The documentation of reduced artemisinin susceptibility in the late 2000s and growing recognition of environmentally driven antifungal resistance have sharpened concern that the small number of available drug classes could be eroded.

Debates

What drives the rise of azole-resistant fungi?

Resistance is selected both by clinical drug use and, for some fungi, by exposure to agricultural azole fungicides in the environment, raising debate over how much each source contributes and how stewardship should span medicine and agriculture.

Key figures

• Matthew Fisher
• Leah Cowen
• Arjen Dondorp

Seminal works

• cowen-2015
• fisher-2018
• dondorp-2009

Frequently asked questions

How do fungi become resistant to azole antifungals?

Common routes include mutations in the target gene ERG11/CYP51 that weaken drug binding, overexpression of the target, and increased activity of efflux pumps that reduce the drug's intracellular concentration.

Why is resistance especially worrying for fungi and parasites?

There are only a few antifungal and antiparasitic drug classes, so resistance to even one class meaningfully narrows the options, and for diseases like malaria and invasive fungal infection that can leave few effective alternatives.